Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Beatriz Hernández-Novoa"'
Autor:
Laura-Amanda Vallejo Aparicio, Victoria Neches García, Beatriz Hernández-Novoa, Gregorio Casado, Ferrán Jodar, Marco Pinel, Daniel Callejo Velasco
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Introduction HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection b
Externí odkaz:
https://doaj.org/article/bbed26e2cce74f478f2a9a4614a0aee3
Autor:
María Rosa López-Huertas, Carolina Gutiérrez, Nadia Madrid-Elena, Beatriz Hernández-Novoa, Julián Olalla-Sierra, Montserrat Plana, Rafael Delgado, Rafael Rubio, María Ángeles Muñoz-Fernández, Santiago Moreno
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Human immunodeficiency virus (HIV) remains incurable due to latent viral reservoirs established in non-activated CD4 T cells that cannot be eliminated via antiretroviral therapy. Current efforts to cure HIV are focused on identifying drugs t
Externí odkaz:
https://doaj.org/article/d1d63f1fdd2b4f53a1ec286acb22c2ef
Autor:
Carolina Gutiérrez, Laura Díaz, Alejandro Vallejo, Beatriz Hernández-Novoa, María Abad, Nadia Madrid, Viktor Dahl, Rafael Rubio, Ana M Moreno, Fernando Dronda, José Luis Casado, Enrique Navas, María Jesús Pérez-Elías, Javier Zamora, Sarah Palmer, Eduardo Muñoz, María Ángeles Muñoz-Fernández, Santiago Moreno
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e27864 (2011)
The primary objective was to assess the effect of MVC intensification on latently infected CD4(+) T cells in chronically HIV-1-infected patients receiving antiretroviral therapy.We performed an open-label pilot phase II clinical trial involving chron
Externí odkaz:
https://doaj.org/article/7e06c4df50d74c84b731c758328cd223
Autor:
Miguel Ángel, Calleja-Hernández, José Manuel, Martinez-Sesmero, Laura Amanda, Vallejo-Aparicio, Beatriz, Hernández-Novoa, Xavier, Badia
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(4)
To determine the value contribution of cabotegravir + rilpivirine, the first injectable every two months long-acting antiretroviral regimen, using multi-criteria decision analysis.The study was developed in two phases. After a small pilot, a field or
Autor:
Rafael Coll Delgado, Santiago Moreno, Carolina Gutierrez, Julián Olalla-Sierra, María Rosa López-Huertas, Rafael M. Rubio, Nadia Madrid-Elena, María Ángeles Muñoz-Fernández, Beatriz Hernández-Novoa, Montserrat Plana
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Human immunodeficiency virus (HIV) remains incurable due to latent viral reservoirs established in non-activated CD4 T cells that cannot be eliminated via antiretroviral therapy. Current efforts to cure HIV are focused on identifying drugs that will
Autor:
Beatriz Hernández-Novoa, Rafael M. Rubio, José Manuel Martínez-Sesmero, Celia Roldán, Javier Sánchez-Rubio, José Luis Poveda, Esteban Ribera, Juan Pasquau, Alejandro Pérez-Mitru
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica. 36:157-164
Resumen Introduccion El objetivo de este estudio es estimar el impacto economico en Espana de la optimizacion del tratamiento antirretroviral (TAR) triple en pacientes con carga viral suprimida segun las recomendaciones GeSIDA/PNS (2015) y su aplicab
Autor:
Alberto Rastrojo, José Alcamí, Mayte Pérez-Olmeda, Francisco Díez-Fuertes, Almudena Cascajero, Beatriz Hernández-Novoa, Begoña Aguado, Santiago Moreno
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Instituto de Salud Carlos III (ISCIII)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
In this study, we have characterized quasispecies dynamics and the evolution of viral tropism in naive HIV-1-infected patients treated with a short course of maraviroc monotherapy (ClinicalTrials.gov registration no. NCT01060618) independently of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea93be80b64fa1436a4b94a7e593ba5
https://europepmc.org/articles/PMC5952159/
https://europepmc.org/articles/PMC5952159/
Autor:
María Laura García-Bermejo, María Coronel Díaz, Beatriz Hernández-Novoa, Alberto Diaz de Santiago, María Rosa López-Huertas, Carolina Gutiérrez, Nadia Madrid-Elena, Fernando Dronda, Ester Dominguez, Sergio Serrano-Villar, Santiago Moreno, Beatriz Sastre
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Maraviroc is a CCR5 antagonist used in the treatment of HIV-1 infection. We and others have suggested that maraviroc could reactivate latent HIV-1. To test the latency-reversing potential of maraviroc and the mechanisms involved, we performed a phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca17180d19dc54cb0c1c33a63019e1c
https://europepmc.org/articles/PMC5899181/
https://europepmc.org/articles/PMC5899181/
Autor:
María Ángeles Muñoz-Fernández, María Abad-Fernández, Sacramento Moreno, L. E. Díaz, Antonio Vallejo, C Gutiérrez, Nadia Madrid, Beatriz Hernández-Novoa
Publikováno v:
HIV Medicine. 16:15-23
Objectives In view of the fact that mucosal damage associated with HIV-1 infection leads to microbial translocation despite successful antiretroviral treatment, we analysed microbial translocation and expression of the gut-homing β7 receptor on peri
Autor:
Sonia Moreno, Ignacio Santos, Beatriz Hernández-Novoa, R Rubio, Belén Alejos, José López-Aldeguer, Inma Jarrín, José Ramón Blanco, M Riera, Antonio Antela, Félix Gutiérrez
Publikováno v:
HIV Medicine. 15:547-556
Objectives We compared reasons for the choice of regimen, time to and reasons for third drug modification, virological response and change in CD4 T-cell counts in patients started on atazanavir/ritonavir (ATV/r)- vs. efavirenz (EFV)-based first-line